Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited
| Autor: | E. John Wherry, Elizabeth M. Jaffee, Trevan Locke, Katie M. Campbell, Antoni Ribas, Gypsyamber D'Souza, Rajarshi Sengupta, Sayyed Kaleem Zaidi, Jean-Charles Soria, John M. Carethers |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Risk
0301 basic medicine medicine.medical_specialty COVID-19 Vaccines MEDLINE Article Virus 03 medical and health sciences 0302 clinical medicine Immune system Risk Factors Immunity Odds Ratio medicine Humans Intensive care medicine Proportional Hazards Models Health Care Rationing Immunization Programs business.industry Proportional hazards model Vaccination COVID-19 Cancer Odds ratio medicine.disease Treatment Outcome 030104 developmental biology Oncology Hematologic Neoplasms 030220 oncology & carcinogenesis Public Health business |
| Zdroj: | Cancer Discov |
| ISSN: | 2159-8290 2159-8274 |
| DOI: | 10.1158/2159-8290.cd-20-1817 |
| Popis: | Summary:Published series on COVID-19 support the notion that patients with cancer are a particularly vulnerable population. There is a confluence of risk factors between cancer and COVID-19, and cancer care and treatments increase exposure to the virus and may dampen natural immune responses. The available evidence supports the conclusion that patients with cancer, in particular with hematologic malignancies, should be considered among the very high-risk groups for priority COVID-19 vaccination. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|